Bristol-Myers SquibbBMY
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees: 34,100
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
44% more funds holding in top 10
Funds holding in top 10: 18 [Q2] → 26 (+8) [Q3]
33% more first-time investments, than exits
New positions opened: 260 | Existing positions closed: 196
20% more capital invested
Capital invested by funds: $64.7B [Q2] → $77.9B (+$13.1B) [Q3]
3% more funds holding
Funds holding: 2,107 [Q2] → 2,171 (+64) [Q3]
6% less call options, than puts
Call options by funds: $1.88B | Put options by funds: $1.99B
2.57% less ownership
Funds ownership: 76.91% [Q2] → 74.35% (-2.57%) [Q3]
12% less repeat investments, than reductions
Existing positions increased: 782 | Existing positions reduced: 890
Research analyst outlook
16 Wall Street Analysts provided 1 year price targets over the past 3 months
16 analyst ratings
Citigroup Andrew Baum 25% 1-year accuracy 1 / 4 met price target | 7%upside $60 | Neutral Maintained | 12 Nov 2024 |
BMO Capital Evan Seigerman 47% 1-year accuracy 7 / 15 met price target | 9%upside $61 | Market Perform Maintained | 12 Nov 2024 |
Morgan Stanley Terence Flynn 31% 1-year accuracy 5 / 16 met price target | 31%downside $39 | Underweight Maintained | 12 Nov 2024 |
Leerink Partners David Risinger 38% 1-year accuracy 3 / 8 met price target | 30%upside $73 | Outperform Upgraded | 12 Nov 2024 |
BMO Capital Evan Seigerman 47% 1-year accuracy 7 / 15 met price target | 1%upside $57 | Market Perform Maintained | 1 Nov 2024 |
Financial journalist opinion
Based on 47 articles about BMY published over the past 30 days
